Matt advises companies, investors and financial institutions in a broad range of public and private debt financings, including secured and unsecured credit facilities, convertible and high-yield bonds and various structured financings.
NeuroPace Secures up to $75 Million in Debt Financing
June 4, 2025
Cooley advised NeuroPace (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, on its $75 million credit facility with MidCap Financial, consisting of a $60 million term loan and a $15 million revolving credit facility.
Oberland Capital Invests up to $600 Million in Biohaven
April 28, 2025
Cooley advised Oberland Capital, a private investment firm committed to funding innovation across the global healthcare industry, on its agreement to invest up to $600 million in Biohaven (NYSE: BHVN), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases.
Battery Ventures-Backed PageUp To Be Acquired by EQT Partners
October 31, 2024
Cooley advised Battery Ventures, a global, technology-focused investment firm, and PageUp Group, a human resources and talent software company that had been majority owned by Battery, on the sale of PageUp to EQT Group.
Cooley advised TriSalus Life Sciences, an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors, on the closing of a debt financing facility for up to $50 million with OrbiMed. Partners Mischi a Marca and Matt Browne led the Cooley team advising TriSalus.
Everbridge Enters Into Definitive Agreement to Be Acquired by Thoma Bravo for $1.8 Billion
March 1, 2024
Cooley advised Everbridge, a global leader in critical event management and national public warning solutions, on its definitive agreement to be acquired by Thoma Bravo in an all-cash transaction valuing Everbridge at approximately $1.8 billion.
